581813-20-9 Usage
Uses
Used in Pharmaceutical Industry:
2-Chloro-4-(trifluoromethyl)benzylamine serves as a building block in the synthesis of various drugs. Its unique structure allows it to be a key component in the development of new pharmaceutical compounds, contributing to the advancement of medicinal chemistry.
Used in Medicinal Chemistry:
2-Chloro-4-(trifluoromethyl)benzylamine is utilized in medicinal chemistry for its potential to generate diverse nitrogen-containing heterocycles. These heterocycles are essential components in many pharmaceutical compounds, making 2-Chloro-4-(trifluoromethyl)benzylamine a valuable asset in drug discovery and development.
Used in Material Development:
2-Chloro-4-(trifluoromethyl)benzylamine has shown promise in the development of new materials, indicating its potential use in various applications beyond the pharmaceutical sector.
Used in Chemical Research:
2-Chloro-4-(trifluoromethyl)benzylamine is also valuable in the field of chemical research, where it can be employed to explore new reactions and mechanisms, further expanding the understanding of organic chemistry and its applications.
Check Digit Verification of cas no
The CAS Registry Mumber 581813-20-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,8,1,8,1 and 3 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 581813-20:
(8*5)+(7*8)+(6*1)+(5*8)+(4*1)+(3*3)+(2*2)+(1*0)=159
159 % 10 = 9
So 581813-20-9 is a valid CAS Registry Number.
581813-20-9Relevant academic research and scientific papers
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
-
, (2008/06/13)
Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
-
Page/Page column 59, (2010/02/11)
Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS
-
Page/Page column 183-184, (2008/06/13)
The invention relates to amide compounds of general formula (I), in which the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. The invention further relates to medicaments comprising at least one of said amides. Said medicaments are suitable for the treatment of metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia, and diabetes as a result of the MCH receptor antagonism.
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
-
, (2008/06/13)
Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
